| Subject: | FDA Updates Warnings, Precautions, Adverse Reactions and Dosage and Administration for Erbitux |
| Category: | Food and Drug Administration (FDA)
|
| Published: | Mon, 19 Sep 2005 - 10:00 am |
| Audience - Oncologists and other healthcare professionals
On 9-14-05 the FDA notified healthcare professionals of changes to the WARNINGS, PRECAUTIONS, ADVERSE REACTIONS, and DOSAGE AND ADMINISTRATION sections of the prescribing information for Erbitux (cetuximab), indicated for the treatment of epidermal growth factor receptor (EGFR) expressing metastatic colorectal carcinoma.
The WARNINGS section has been revised to include a recommendation for a 1-hour observation period following the... The full article is available to StayAlert subscribers. Click here for a free trial subscription. |
|
RESOURCES:
Customizable Documents and Tools:
Related MCN Products:
|
|
StayAlert! notifies healthcare customers of all federal and regulatory body legislation changes impacting the healthcare industry, including TJC (JCAHO), CDC, CMS, DHHS, FDA, OSHA, OIG and many others. StayAlert! complements this with regulatory implementation action plans. StayAlert! serves as a virtual healthcare department, augmenting traditional employee staffed departments and freeing employees to perform other vital functions. The strength of StayAlert! rests in its ability to allow healthcare organizations to streamline their businesses using the Internet as a foundation architecture. StayAlert! provides cost containment and reduction through elimination of unnecessary overhead, and work caused by errors or poor access to information. |
|